Abstract
Azidothymidine (AZT) was introduced into curdlan by biodegradable ester bond to give AZT-bound curdlan (AZT-curdlan) in order to aim at releasing AZT from the polymer backbone by an enzymatic hydrolysis in living organs. Structure of the AZT-curdlan was analyzed by 13C NMR and 1H-13C COSY-FG 2D-NMR spectroscopy, indicating that AZT was bound to C6 hydroxyl group of curdlan as designed. Subsequently, the AZT-curdlan was sulfated with sulfur trioxide-pyridine complex to give sulfated AZT-curdlans (AZT-curdlan sulfates). AZT-curdlan sulfates, in vitro, exhibited anti-HIV activities in the EC50 range of 0.20 to 0.60 μg ml−1, corresponding to that (EC50=0.50 μg ml−1) of highly active curdlan sulfate. They possessed low cytotoxicities of CC50 more than 1000 μg ml−1 in vitro, indicating that AZT was not released in vitro. However, an increase in the anti-HIV activity and the cytotoxicity was observed when the AZT-curdlan sulfate solution in 90% buffer at pH 7.4 and 10% dimethyl sulfoxide mixture was kept in a refrigerator for a few weeks. The phenomenon indicates that an anti-HIV active AZT was released slowly from the curdlan sulfate carrier. Furthermore, the AZT-curdlan sulfates exhibited low to moderate anticoagulant activities in vitro.
Similar content being viewed by others
Article PDF
References
G. Pantaleo, C. Graziosi, J. F. Demarest, L. Butin, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci, Nature, 362, 355 (1993).
J. Embretson, M. Zupancic, J. L. Ribas, A. Burke, P. Racz, K. Tenner-Racz, and A. S. Haase, Nature, 362, 359 (1993).
M. Seligmann, D. A. Warrell, J. P. Aboulker, C. Carbon, J. H. Darbyshire, J. Dormont, E. Eschwege, D. J. Girling, D. R. James, J. P. Levy, T. E. A. Peto, D. Schwarz, A. B. Stone, I. V. D. Weller, R. Withnall, K. Gelmon, E. Lafon, A. M. Swart, V. R. Aber, A. G. Babiker, S. Lhoro, A. J. Nunn, and M. Vray, Lancet, 343, 871 (1994).
K. K. Manouilov, I. I. Fedorov, F. D. Boudinot, C. A. White, L. P. Kotra, R. F. Schinazi, C. D. II. Hong, and C. K. Chu, Antiviral Chem. Chemother., 6, 230 (1995).
K. K. Manouilov, C. A. White, F. D. Boudinot, I. I. Fedorov, and C. K. Chu, Drug Metabolism and Disposition, 23, 655 (1995).
B. A. Larder, G. Darby, and D. D. Richman, Science, 243, 1731 (1989).
M. Baba, D. Schols, R. Pauwels, H. Nakashima, and E. De-Clercq, J. Acquired Immunodeficiency Syndromes, 3, 493 (1990).
M. Holodniy, S. Kim, D. Katzenstein, M. Konrad, E. Groves and T. C. Merigan, J. Clin. Microbiol., 29, 676 (1991).
T. Moriya, H. Kurita, K. Matsumoto, T. Otake, H. Mori, M. Morimoto, N. Ueba, and N. Kunita, J. Med. Chem., 34, 2301 (1991).
E. Mbemba, V. Chams, J. C. Gluckman, D. Klatzmann, and L. Gattegno, Biochim. Biophys. Acta, 62, 1138 (1992).
R. Ueno and S. Kuno, Lancet, 13, 1397 (1987).
H. Mitsuya, D. J. Looney, S. Kuno, R. Ueno, F. W. Staal, and S. Broder, Science, 240, 646 (1988).
C. Flexner, P. A. Barditch-crovo, D. M. Kornhauser, H. Farzadegan, L. J. Nerhood, R. E. Chaisson, K. M. Bell, K. J. Lorentsen, C. W. Hendrix, B. G. Petty, and P. S. Lietman, Antimicrob. Agents Chemother., 35, 2544 (1991).
K. Hatanaka, T. Yoshida, T. Uryu, O. Yoshida, H. Nakashima, N. Yamamoto, T. Mimura, and Y. Kaneko, Jpn. J. Cancer Res., 80, 95 (1989).
Y. Kaneko, O. Yoshida, R. Nakagawa, T. Yoshida, M. Date, S. Ogihara, T. Shioya, Y. Matsuzawa, H. Shinkai, N. Yasuda, K. Matsuzaki, T. Uryu, and N. Yamamoto, Biochem. Pharmacol., 25, 163 (1990).
T. Yoshida, K. Hatanaka, T. Uryu, Y. Kaneko, E. Suzuki, H. Miyano, T. Mimura, O. Yoshida, and N. Yamamoto, Macromolecules, 23, 3717 (1990).
T. Uryu, N. Ikushima, K. Katsuraya, T. Shoji, N. Takahashi, T. Yoshida, K. Kanno, T. Murakami, H. Nakashima, and N. Yamamoto, Biochem. Pharmacol., 43, 2385 (1992).
K. Katsuraya, N. Ikushima, N. Takahashi, T. Shoji, H. Nakashima, N. Yamamoto, T. Yoshida, and T. Uryu, Carbohydr. Res., 260, 51 (1994).
K. Katsuraya, T. Shibuya, K. Inazawa, H. Nakashima, N. Yamamoto, and T. Uryu, Macromolecules, 28, 6697 (1995).
M. Gordon, M. Guralnik, Y. Kaneko, T. Mimura, M. Baker, and W. Lang, J. Med., 25, 163 (1994).
T. Uryu, Y. Kaneko, T. Yoshida, R. Mihara, T. Shoji, K. Katsuraya, H. Nakashima, and N. Yamamoto, in Carbohydrates and Carbohydrates Polymer, M. Yalpani, Ed., ATL Press, Mount Prospect, IL, 1993, p 101.
Y. Gao, A. Fukuda, K. Katsuraya, Y. Kaneko, T. Mimura, H. Nakashima, and T. Uryu, Macromolecules, 30, 3224 (1997).
R. Pauwels, J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq, J. Virol. Methods, 20, 309 (1988).
K. Hatanaka, T. Yoshida, S. Miyahara, T. Sato, F. Ono, T. Uryu, and H. Kuzuhara, J. Med. Chem., 30, 810 (1987).
T. Yoshida, Y. Yasuda, T. Uryu, H. Nakashima, N. Yamamoto, T. Mimura, and Y. Kaneko, Macromolecules, 27, 6272 (1994).
T. Yoshida, Y. Yasuda, T. Mimura, Y. Kaneko, H. Nakashima, N. Yamamoto, and T. Uryu, Carbohydr. Res., 276, 425 (1995).
T. Kawaguchi, K. Ishikawa, T. Seki, and K. Juni, J. Pharm. Sci., 79, 531 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gao, Y., Katsuraya, K., Kaneko, Y. et al. Synthesis of Azidothymidine-Bound Curdlan Sulfate with Anti-Human Immunodeficiency Virus Activity in vitro. Polym J 30, 31–36 (1998). https://doi.org/10.1295/polymj.30.31
Issue Date:
DOI: https://doi.org/10.1295/polymj.30.31
Keywords
This article is cited by
-
Syntheses and anti-AIDS activities of polyrotaxane-3′-azido-3′-deoxythymidine conjugates
Macromolecular Research (2006)
-
Ester Derivatives of Nucleoside Inhibitors of Reverse Transcriptase: 2. Molecular Systems for the Combined Therapy with 3′-Azido-3′-Deoxythymidine and 2′,3′-Didehydro-3′-Deoxythymidine
Russian Journal of Bioorganic Chemistry (2005)